Recent

% | $
Quotes you view appear here for quick access.

Guided Therapeutics, Inc Message Board

  • tonoos tonoos Jul 10, 2013 9:30 AM Flag

    From PT 3-12-13 (relax, repetitive WHINERS)

    Since inception, the company has been well focused on what was needed for the patients, doctors and payers and has produced a superior product.Medical device development from inception to market cost on average about $94 million; Guided Therapeutics has spent approximately $40 million on the LuViva development program of which half has been non-dilutive.

    This is a pivotal year for Guided Therapeutics, a company few have heard of because of its microcap status and bulletin board listing. Current valuation in no way represents the trajectory of the company in the near and longer term. LuViva is a superior product that will disrupt the cervical cancer screening market and provide screening in new markets. Once acceptance of the product in the market place is assured, Guided Therapeutics will be a very attractive acquisition with large addressable markets, a rich pipeline, little competition and strong intellectual property. Building an early position ahead of near term catalysts outweighs the risk of a small capital raise. For those with longer-term horizons this could be a little gem.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GTHP.OB
0.298+0.001(+0.34%)Oct 30 2:14 PMEDT